While the benefit of CeO2 surface oxygen vacancies for CO2 methanation¬ is well established, their role under photothermal conditions has not been probed in depth. In this work, SiO2 was...
The presence of defects in a catalyst support is known to benefit catalytic activity. In this work, a He-plasma treatment-based strategy for introducing and stabilising defects on a Ni/TiO2 catalyst for photothermal CO2 hydrogenation was established. The impact of pretreatment step sequence—which comprised He-plasma treatment and reduction/passivation—on defect generation and stabilisation within the support was evaluated. Characterisation of the Ni/TiO2 catalysts indicated that defects created in the TiO2 support during the initial plasma treatment stage were then stabilised by the reduction/passivation process, (P-R)Ni/TiO2. Conversely, performing reduction/passivation first, (R-P)Ni/TiO2, invoked a resistance to subsequent defect formation upon plasma treatment and consequently, poorer photothermal catalytic activity. The plasma treatment altered the metal-support interaction and ease of catalyst reduction. Under photothermal conditions, (P-R)Ni/TiO2 reached the highest methane production in 75 min, while (R-P)Ni/TiO2 required 165 min. Decoupling the impacts of light and heat indicated thermal dominance of the reaction with CO2 conversion observed from 200 °C onwards. Methane was the primary product with carbon monoxide detected at 350 °C (~2%) and 400 °C (~5%). Overall, the findings demonstrate the importance of pretreatment step sequence when utilising plasma treatment to generate active defect sites in a catalyst support.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.